 -- NUZYRA omadacycline Generated Net U.S. Sales of 13.2 Million in the First Quarter 2021; 6 Increase Over the Fourth Quarter 2020 -- BARDA has Initiated the First Procurement of NUZYRA Valued at 38 Million in the Second Quarter of 2021 -- NUZYRA Expansion into the Primary Care Setting Underway 